发布求助
文献互助 智能选刊 最新文献

Clinical Lipidology最新文献

筛选
英文 中文
The withdrawal of the thyromimetic eprotirome 促甲状腺素的停药
Clinical Lipidology Pub Date : 2014-10-01 DOI: 10.2217/clp.14.29
M. France
{"title":"The withdrawal of the thyromimetic eprotirome","authors":"M. France","doi":"10.2217/clp.14.29","DOIUrl":"https://doi.org/10.2217/clp.14.29","url":null,"abstract":"Abstract “Despite the disappointing discontinuation of eprotirome, these studies have provided valuable information on the effects of TR-β specific agonists in man.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"47 2 1","pages":"483 - 486"},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89188482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Examining controversies and new frontiers in lipid management 检查血脂管理的争议和新领域
Clinical Lipidology Pub Date : 2014-10-01 DOI: 10.2217/clp.14.38
S. Nicholls
{"title":"Examining controversies and new frontiers in lipid management","authors":"S. Nicholls","doi":"10.2217/clp.14.38","DOIUrl":"https://doi.org/10.2217/clp.14.38","url":null,"abstract":"Abstract Over the course of the last three decades our approach to the management of dyslipidemia has intensified on the basis of randomized controlled trials demonstrating reduction in cardiovascular events. However, the presence of a substantial residual risk and complex dyslipidemic states presents an ongoing challenge in clinical practice. The current controversies and opportunities in the management of both atherogenic and protective lipid factors will be reviewed.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"9 1","pages":"587 - 595"},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81809301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression 多发性硬化症中的脂质:不利的脂质谱、残疾和疾病进展
Clinical Lipidology Pub Date : 2014-10-01 DOI: 10.2217/clp.14.41
Prudence Tettey, I. A. van der Mei
{"title":"Lipids in multiple sclerosis: adverse lipid profiles, disability and disease progression","authors":"Prudence Tettey, I. A. van der Mei","doi":"10.2217/clp.14.41","DOIUrl":"https://doi.org/10.2217/clp.14.41","url":null,"abstract":"Abstract “The peroxidation of lipoproteins and their associated serum lipids have been implicated as potential agents involved in demyelination and axonal injury in multiple sclerosis.”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"3 1","pages":"473 - 475"},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74240857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Utilizing liposomes and lipid nanoparticles to overcome challenges in breast cancer treatment 利用脂质体和脂质纳米颗粒克服乳腺癌治疗中的挑战
Clinical Lipidology Pub Date : 2014-10-01 DOI: 10.2217/clp.14.48
Reyhaneh Varshochian, Hosniyeh Hosseinzadeh, N. Gandomi, Faranak Tavassolian, F. Atyabi, R. Dinarvand
{"title":"Utilizing liposomes and lipid nanoparticles to overcome challenges in breast cancer treatment","authors":"Reyhaneh Varshochian, Hosniyeh Hosseinzadeh, N. Gandomi, Faranak Tavassolian, F. Atyabi, R. Dinarvand","doi":"10.2217/clp.14.48","DOIUrl":"https://doi.org/10.2217/clp.14.48","url":null,"abstract":"Abstract Various lipid particulate drug delivery systems with liposomes as forefront have attracted increasing attention in cancer treatment, especially breast cancer therapy. Multidrug resistance and off-target cytotoxicity are among major obstacles faced by researchers in this area. To address these problems, various strategies, such as composition modifications, pegylation and attaching the targeting ligands, have been investigated. In this regard, a number of liposomal therapeutics could successfully reach the market and also several preclinical and clinical approaches are ongoing to upgrade lipid particles to multipotential carriers and potentiate their therapeutic efficacies. The current review is mainly concentrated on recent approaches in liposomal drug delivery systems intended for breast cancer therapy, and will have a glance at novel attributed studies based on other particulate lipid carriers.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"20 1","pages":"571 - 585"},"PeriodicalIF":0.0,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89394661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Cholesterol removal from plaques and elimination from the body: change in paradigm to reduce risk for heart disease 从斑块中去除胆固醇和从体内消除胆固醇:改变模式以降低心脏病的风险
Clinical Lipidology Pub Date : 2014-08-01 DOI: 10.2217/clp.14.35
Shobha Ghosh, Jinghua Bie, Jing Wang, Quan Yuan, Siddhartha S Ghosh
{"title":"Cholesterol removal from plaques and elimination from the body: change in paradigm to reduce risk for heart disease","authors":"Shobha Ghosh, Jinghua Bie, Jing Wang, Quan Yuan, Siddhartha S Ghosh","doi":"10.2217/clp.14.35","DOIUrl":"https://doi.org/10.2217/clp.14.35","url":null,"abstract":"Abstract Accumulation of lipid-laden macrophage foam cells in arterial wall is the hallmark of atherosclerosis, the underlying cause of cardiovascular disease (CVD). Increased uptake of cholesteryl ester-rich modified low-density lipoprotein (LDL) is thought to be responsible for lipid accumulation and strong inverse correlation exists between plasma LDL and CVD. However, despite reaching the target LDL levels significant residual risk for CVD remains. Furthermore, current therapeutic strategies do not lead to regression of existing plaques. This review discusses a change in paradigm emphasizing the importance of removal of cholesterol from macrophage foam cells and final elimination of cholesterol from the body. Intracellular processes involved in this process are described to provide insight into the development of new therapies for CVD.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"43 1","pages":"429 - 440"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77408298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Efficacy and safety of ezetimibe plus atorvastatin therapy 依zetimibe联合阿托伐他汀治疗的有效性和安全性
Clinical Lipidology Pub Date : 2014-08-01 DOI: 10.2217/clp.14.36
J. Foody, P. Toth, A. Tershakovec, T. Musliner, J. Tomassini, R. Lowe, D. Neff, H. Davis
{"title":"Efficacy and safety of ezetimibe plus atorvastatin therapy","authors":"J. Foody, P. Toth, A. Tershakovec, T. Musliner, J. Tomassini, R. Lowe, D. Neff, H. Davis","doi":"10.2217/clp.14.36","DOIUrl":"https://doi.org/10.2217/clp.14.36","url":null,"abstract":"Abstract Statin therapy is highly effective in reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events; however, many high-risk patients on statin monotherapy do not achieve sufficient LDL-C lowering. Statin-dose uptitration, switching to more potent statins and/or addition of complementary lipid-lowering drugs has been recommended for these patients. Numerous clinical trials have shown that coadministration of statins with cholesterol absorption inhibitor, ezetimibe, improves LDL-C lowering and other lipid parameters more than statins alone, including doubling the statin dose. In clinical outcome trials, ezetimibe combined with simvastatin reduced ischemic events in high-risk patients with chronic kidney disease and aortic stenosis; the incremental benefit of LDL-C lowering when ezetimibe is added to statin therapy on cardiovascular risk reduction compared with statin monotherapy is currently being evaluated in an ongoing clinical trial. Recently, a fixed-dose combination of ezetimibe plus atorvastatin, a statin with greater potency than most other statins, was approved by the US FDA and offers a therapeutic option for high-risk patients who do not achieve recommended LDL-C levels on statin monotherapy. This article provides an update on the safety and efficacy of ezetimibe plus atorvastatin therapy.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"52 3 1","pages":"441 - 470"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90923340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Influence of exercise training on HDL function 运动训练对HDL功能的影响
Clinical Lipidology Pub Date : 2014-08-01 DOI: 10.2217/clp.14.34
V. Adams, S. Erbs
{"title":"Influence of exercise training on HDL function","authors":"V. Adams, S. Erbs","doi":"10.2217/clp.14.34","DOIUrl":"https://doi.org/10.2217/clp.14.34","url":null,"abstract":"Abstract “Besides promotion of reverse cholesterol transport, HDL has been shown to exert beneficial antiatherogenic effects...”","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"10 1","pages":"395 - 398"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78195613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Association of lipoprotein subclasses and carotid intima-media thickness in the Chinese population 脂蛋白亚类与中国人群颈动脉内膜-中膜厚度的关系
Clinical Lipidology Pub Date : 2014-08-01 DOI: 10.2217/clp.14.22
Fangfang Yan, L. Tian, Huangdao Yu, A. Baskota, Yun-Yi Gao, Sheyu Li, M. Fu, H. Tian
{"title":"Association of lipoprotein subclasses and carotid intima-media thickness in the Chinese population","authors":"Fangfang Yan, L. Tian, Huangdao Yu, A. Baskota, Yun-Yi Gao, Sheyu Li, M. Fu, H. Tian","doi":"10.2217/clp.14.22","DOIUrl":"https://doi.org/10.2217/clp.14.22","url":null,"abstract":"Abstract Aims: To determine whether lipoprotein subclasses are associated with the carotid intima-media thickness (IMT) in Chinese population. Patients & methods: Total cholesterol (TC), triglycerides, high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) were measured by standard enzymatic methods. The subclasses of LDL were determined by 1D gradient gel electrophoresis and subclasses of HDL were determined by 2D gradient gel electrophoresis in 342 participants. Carotid IMT was measured by means of high-resolution vascular ultrasound. Results: In multivariate analysis, TC and LDL-C levels were positively correlated with the carotid IMT (p < 0.001). In stepwise multiple regression analysis, small dense LDL was found to be significantly associated with IMT after adjustment for other metabolic risks and traditional lipids such as triglycerides, TC and HDL-C. Additionally, HDL subclasses were not correlated with IMT. Conclusion: Small dense LDL was a stronger predictor for carotid atherosclerosis in the general Chinese population when compared with HDL-C or HDL subclasses, which is independent of lipids and other related metabolic risks.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"18 1","pages":"407 - 415"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84018660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia 处方omega-3羧酸治疗严重高甘油三酯血症
Clinical Lipidology Pub Date : 2014-08-01 DOI: 10.2217/clp.14.39
K. Maki, S. Poulos, Alyssa K Phillips, A. Lawless
{"title":"Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia","authors":"K. Maki, S. Poulos, Alyssa K Phillips, A. Lawless","doi":"10.2217/clp.14.39","DOIUrl":"https://doi.org/10.2217/clp.14.39","url":null,"abstract":"Abstract The role of omega-3 (OM3) fatty acids in the reduction of elevated triglycerides is well recognized. This has prompted the development of concentrated OM3 drugs for the treatment of hypertriglyceridemia, a condition that may increase risk for cardiovascular disease and pancreatitis. Intestinal absorption of currently available OM3 ethyl ester drugs depends on the activity of pancreatic lipases, largely stimulated by dietary fat. As many patients with severe hypertriglyceridemia are advised to minimize fat intake, there is a need for a product with high bioavailability, irrespective of meal timing and fat content. This review will discuss a novel OM3 carboxylic acid drug (Epanova®, AstraZeneca, DE, USA) that has been approved as an adjunct to diet for the treatment of severe hypertriglyceridemia.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"41 1","pages":"399 - 406"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80401229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Diet and lifestyle interventions on lipids: combination with genomics and metabolomics 饮食和生活方式对血脂的干预:结合基因组学和代谢组学
Clinical Lipidology Pub Date : 2014-08-01 DOI: 10.2217/clp.14.30
Yan Zheng, L. Qi
{"title":"Diet and lifestyle interventions on lipids: combination with genomics and metabolomics","authors":"Yan Zheng, L. Qi","doi":"10.2217/clp.14.30","DOIUrl":"https://doi.org/10.2217/clp.14.30","url":null,"abstract":"Abstract Lipids have been closely related to risk of a variety of metabolic disorders such as cardiovascular disease and diabetes. Compelling evidence has shown that diet/lifestyle interventions may affect circulating lipid profile; research in genetics has associated more than 150 common variants with lipid traits. In recent years, emerging data from observational studies and randomized clinical trials have shown that dietary and lifestyle factors might interact with genetic factors in determining lipid levels. In addition, the emerging ‘omics’ research, especially lipidomics, owns potentials to provide comprehensive insights into the mechanisms underlying gene–diet/lifestyle interactions. Although many challenges exist, studies in these areas hold promise to inform future personalized diet and lifestyle interventions on improvement of lipids and mitigate the related disorders.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"61 1","pages":"417 - 427"},"PeriodicalIF":0.0,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88155024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信